161 related articles for article (PubMed ID: 19880966)
1. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Fendrich V; Chen NM; Neef M; Waldmann J; Buchholz M; Feldmann G; Slater EP; Maitra A; Bartsch DK
Gut; 2010 May; 59(5):630-7. PubMed ID: 19880966
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
Fendrich V; Sparn M; Lauth M; Knoop R; Plassmeier L; Bartsch DK; Waldmann J
Pancreatology; 2013; 13(5):502-7. PubMed ID: 24075515
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin.
Sclabas GM; Uwagawa T; Schmidt C; Hess KR; Evans DB; Abbruzzese JL; Chiao PJ
Cancer; 2005 Jun; 103(12):2485-90. PubMed ID: 15861417
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.
Zhang L; Sanderson SO; Lloyd RV; Smyrk TC
Am J Surg Pathol; 2007 Aug; 31(8):1191-5. PubMed ID: 17667542
[TBL] [Abstract][Full Text] [Related]
5. Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors.
Fendrich V; Lopez CL; Manoharan J; Maschuw K; Wichmann S; Baier A; Holler JP; Ramaswamy A; Bartsch DK; Waldmann J
Endocr Relat Cancer; 2014 Oct; 21(5):813-24. PubMed ID: 25121552
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
Rao CV; Mohammed A; Janakiram NB; Li Q; Ritchie RL; Lightfoot S; Vibhudutta A; Steele VE
Neoplasia; 2012 Sep; 14(9):778-87. PubMed ID: 23019409
[TBL] [Abstract][Full Text] [Related]
7. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
Adsay NV; Basturk O; Cheng JD; Andea AA
Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
[TBL] [Abstract][Full Text] [Related]
8. Modelling a dream: the molecular prevention of pancreatic cancer.
Hawk E; Patterson S
Gut; 2010 May; 59(5):566-8. PubMed ID: 20427387
[No Abstract] [Full Text] [Related]
9. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia.
Swartz MJ; Batra SK; Varshney GC; Hollingsworth MA; Yeo CJ; Cameron JL; Wilentz RE; Hruban RH; Argani P
Am J Clin Pathol; 2002 May; 117(5):791-6. PubMed ID: 12090430
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features of pancreatic intraepithelial neoplasias and their relationship to intraductal papillary-mucinous tumors.
Takaori K; Kobashi Y; Matsusue S; Matsui K; Yamamoto T
J Hepatobiliary Pancreat Surg; 2003; 10(2):125-36. PubMed ID: 14505145
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model.
Ouyang N; Williams JL; Tsioulias GJ; Gao J; Iatropoulos MJ; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2006 Apr; 66(8):4503-11. PubMed ID: 16618778
[TBL] [Abstract][Full Text] [Related]
12. A case of mistaken identity? Nonductal origins of pancreatic "ductal" cancers.
Murtaugh LC; Leach SD
Cancer Cell; 2007 Mar; 11(3):211-3. PubMed ID: 17349578
[TBL] [Abstract][Full Text] [Related]
13. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray.
Maitra A; Adsay NV; Argani P; Iacobuzio-Donahue C; De Marzo A; Cameron JL; Yeo CJ; Hruban RH
Mod Pathol; 2003 Sep; 16(9):902-12. PubMed ID: 13679454
[TBL] [Abstract][Full Text] [Related]
14. Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia.
Abe K; Suda K; Arakawa A; Yamasaki S; Sonoue H; Mitani K; Nobukawa B
Pancreas; 2007 Jan; 34(1):85-91. PubMed ID: 17198188
[TBL] [Abstract][Full Text] [Related]
15. Hypothetical progression model of pancreatic cancer with origin in the centroacinar-acinar compartment.
Esposito I; Seiler C; Bergmann F; Kleeff J; Friess H; Schirmacher P
Pancreas; 2007 Oct; 35(3):212-7. PubMed ID: 17895840
[TBL] [Abstract][Full Text] [Related]
16. Where and when does pancreatic carcinoma start?
Lüttges J; Hahn S; Klöppel G
Med Klin (Munich); 2004 Apr; 99(4):191-5. PubMed ID: 15085289
[TBL] [Abstract][Full Text] [Related]
17. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis.
Adsay NV; Merati K; Andea A; Sarkar F; Hruban RH; Wilentz RE; Goggins M; Iocobuzio-Donahue C; Longnecker DS; Klimstra DS
Mod Pathol; 2002 Oct; 15(10):1087-95. PubMed ID: 12379756
[TBL] [Abstract][Full Text] [Related]
18. The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer.
Lewis BC; Klimstra DS; Varmus HE
Genes Dev; 2003 Dec; 17(24):3127-38. PubMed ID: 14681205
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of pancreatic cancer-one step closer.
Fendrich V
Langenbecks Arch Surg; 2012 Apr; 397(4):495-505. PubMed ID: 22350613
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma.
Andea A; Sarkar F; Adsay VN
Mod Pathol; 2003 Oct; 16(10):996-1006. PubMed ID: 14559982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
